I was reading somewhere there need about $100M or so.
CR is off the cards as it will be too dilutive so it’s a partnership/licensing type deal IMO - they have already given up low teens % royalties (from memory) already so possibly they can given away another 15% in exchange for some more cash
Ann: Opthea Completes Enrollment in Phase 3 Clinical Program, page-23
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.0¢ |
Change
-0.005(0.76%) |
Mkt cap ! $800.2M | |||
| Open | High | Low | Value | Volume |
| 64.0¢ | 65.5¢ | 63.5¢ | $1.977M | 3.065M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13502 | 64.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.5¢ | 15085 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |